Selective vs nonselective beta-blockers.

Short answer: cardioselective agents bind beta-1 receptors with much higher affinity than beta-2 receptors, so at usual doses they largely spare the airways. Nonselective agents block both populations from the start. Selectivity is a ratio, not a switch, and it fades as the dose climbs.

Where the two receptor populations sit

Beta-1 receptors are concentrated in cardiac tissue, where they raise heart rate and contractility, and in the juxtaglomerular cells of the kidney, where they drive renin release. Beta-2 receptors sit in bronchial smooth muscle, where they cause bronchodilation, in vascular smooth muscle of skeletal muscle beds, and in liver and skeletal muscle, where they support glycogenolysis. Every clinical difference between the two classes follows from this distribution, so the receptor map is the thing worth memorising, not the drug lists.

What selectivity means at the receptor

A cardioselective beta-blocker is a competitive antagonist with greater binding affinity for beta-1 than for beta-2. It is not a drug that cannot reach beta-2 receptors. At therapeutic concentrations most occupied receptors are beta-1, so cardiac output and renin release fall while bronchial tone is left largely intact. The word selective describes a preference, and that preference is quantitative, which is exactly why it can be overwhelmed.

Which agents are selective

The classic beta-1 selective agents are acebutolol, atenolol, betaxolol, bisoprolol, esmolol and metoprolol. Their generic names run from A to M, and the nonselective agents that follow include nadolol, penbutolol, pindolol, propranolol, sotalol and timolol, running from N to Z. The alphabet hook is genuinely useful, but it carries three exceptions worth knowing before you rely on it. Carvedilol and labetalol sit in the A to M range yet are nonselective, because both add alpha-1 blockade. Nebivolol sits in the N to Z range yet is beta-1 selective, and it also promotes nitric oxide mediated vasodilation.

Why selectivity fades with dose

Because selectivity is a ratio of affinities, it depends on how much drug is present. As the concentration rises, beta-1 receptors approach saturation and further drug begins occupying beta-2 receptors in clinically meaningful numbers. A high dose of metoprolol therefore produces bronchoconstriction that a low dose would not, and the patient who tolerated the starting dose can deteriorate after titration. Exams test this as a dose relationship rather than a property of the molecule.

Receptor distribution like this is drilled daily inside the PharmBit app, one mechanism, one trap, five minutes.

What nonselective blockade adds

Blocking beta-2 alongside beta-1 produces three consequences that appear constantly in question stems. Bronchial smooth muscle loses its dilating signal, so airway resistance rises and asthma can be provoked. Hepatic and skeletal muscle glycogenolysis is impaired, so recovery from hypoglycaemia slows, compounding the loss of adrenergic warning signs covered in beta-blockers mask hypoglycaemia symptoms. Vascular beta-2 vasodilation is removed while alpha-1 vasoconstriction continues, which is the unopposed alpha effect that makes nonselective agents hazardous in cocaine toxicity and phaeochromocytoma.

The asthma question

Uncontrolled asthma is a contraindication to nonselective agents. Where a beta-blocker is genuinely indicated, for example after myocardial infarction, a cardioselective agent at the lowest effective dose is preferred because bronchial beta-2 receptors are relatively spared. The caution never disappears entirely, since selectivity is partial and dose-dependent. An exam stem pairing asthma with a beta-blocker is asking you to choose selective and keep monitoring, not to refuse the class outright. Chronic obstructive pulmonary disease is treated more permissively than asthma, because the airway obstruction there is largely fixed rather than driven by reversible bronchospasm, so the beta-2 mediated risk is smaller. Distinguishing the two conditions in a stem therefore changes the expected answer even though both involve the airways.

Third-generation agents

Carvedilol and labetalol block beta-1, beta-2 and alpha-1 receptors, so they lower peripheral resistance through alpha blockade while slowing the heart through beta blockade. That combination suits heart failure and hypertensive emergencies, but the beta-2 blockade means they carry the full nonselective airway risk. Nebivolol takes the opposite route, combining beta-1 selectivity with nitric oxide mediated vasodilation. Grouping all three as third-generation hides the fact that two are nonselective and one is not. Nebivolol's vasodilation is also mechanistically distinct from the other two, because it arises from nitric oxide release by the endothelium rather than from alpha-1 blockade on the vessel wall. Two drugs can therefore lower peripheral resistance through entirely different pathways while sharing a generation label, which is a reminder that generation names describe chronology rather than mechanism.

Why stopping abruptly is dangerous

Chronic blockade changes the receptor population itself, which is what makes withdrawal hazardous. When beta receptors are persistently antagonised, the cell compensates by increasing the number of receptors expressed on the surface, a process called upregulation. That compensation is invisible while the drug is present, because the additional receptors are blocked as fast as they appear. Removing the antagonist suddenly exposes an enlarged receptor population to normal circulating catecholamines, so the tissue responds far more strongly than it did before treatment started. Rebound tachycardia and hypertension after abrupt withdrawal are not the disease returning, they are an upregulated receptor population meeting an unchanged catecholamine level. The risk is greatest in patients with ischaemic heart disease, where the resulting rise in heart rate and contractility increases myocardial oxygen demand at exactly the wrong moment. This is why beta-blockers are tapered rather than stopped, and why an exam stem describing chest pain days after a patient ran out of medication is testing upregulation rather than poor adherence in itself.

Lipophilicity decides which drugs reach the brain

Selectivity determines which receptors a drug occupies, and lipophilicity determines which compartments it can reach to find them. Propranolol is highly lipophilic, so it crosses the blood-brain barrier readily and blocks central beta receptors as well as peripheral ones. That central access produces the fatigue, vivid dreams and low mood that appear in question stems, and it is also why propranolol is used deliberately for performance anxiety and essential tremor. Atenolol is hydrophilic, so it largely stays peripheral and causes fewer central effects. The two properties are independent, which is the point students miss: a drug can be cardioselective and lipophilic, or nonselective and hydrophilic, in any combination. The propranolol and atenolol pairing is worked through in propranolol vs atenolol.

Intrinsic sympathomimetic activity

A third property cuts across selectivity again. Some beta-blockers, notably pindolol and acebutolol, are partial agonists rather than pure antagonists, so they produce weak receptor stimulation while blocking the stronger endogenous signal. That partial agonism is called intrinsic sympathomimetic activity, and it means resting heart rate falls less than with a pure antagonist. The practical consequence is that these agents cause less bradycardia at rest while still blunting the response to exercise or stress. Intrinsic sympathomimetic activity is a property of how the drug behaves at the receptor, not of which receptor it prefers, so it is independent of selectivity. Agents with this property are generally avoided after myocardial infarction, because the residual stimulation works against the reduction in cardiac work that makes beta-blockade useful there.

Why heart failure evidence is drug-specific

Beta-blockade in heart failure is the clearest example of class effect failing as an assumption. Only a small number of agents have mortality evidence in chronic heart failure with reduced ejection fraction, principally bisoprolol, carvedilol and metoprolol succinate, and guidelines name those agents rather than the class. Substituting another beta-blocker on the grounds that it also blocks beta-1 is therefore not supported, because the evidence attaches to the specific molecules tested. Selectivity predicts the receptor occupied but never predicts trial evidence, which has to be known separately for each agent. Exam questions that offer atenolol for heart failure are testing exactly this gap between mechanism and evidence.

How exams test selectivity

Asthma plus a beta-blocker expects a cardioselective choice with continued caution. A patient stable on low-dose metoprolol who wheezes after titration is testing dose-dependent loss of selectivity. Cocaine-associated chest pain with propranolol is testing unopposed alpha stimulation. A question naming carvedilol as cardioselective is testing whether you memorised the alphabet rule without its exceptions.

Conclusion

Beta-1 receptors govern the heart and renin release, beta-2 receptors govern the airways, vasculature and glycogenolysis. Cardioselective agents prefer beta-1 but never bind it exclusively, so their advantage narrows as the dose rises. Nonselective blockade adds bronchoconstriction, impaired glucose recovery and unopposed alpha vasoconstriction. Carvedilol, labetalol and nebivolol are the exceptions that make the alphabet hook safe to use.

Practice questions

For study only. This post explains pharmacology concepts for exam preparation. It is not medical advice. Always follow your course materials, formulary, and supervisor guidance for clinical decisions.

Keep reading

ACE inhibitors vs ARBs: cough, angioedema and pregnancy differences 2026

Bradykinin cough, angioedema rules and pregnancy contraindications compared. The exam-trap pair in six minutes.

Mycin vs micin: one letter, two organisms

The endings mark the organism that produced the antibiotic, not how it works. Why gentamicin and erythromycin are spelled differently and share nothing else.

Bactericidal vs bacteriostatic antibiotics

A laboratory definition, not a clinical one. What the MBC/MIC ratio means, why it shifts between labs, and what trials in severe infection actually found.

Morphine vs codeine: why CYP2D6 decides which works

Codeine is a prodrug activated by CYP2D6, morphine is not. Poor and ultra-rapid metabolisers, and the exam trap.